Skip to main content
Top
Literature
5.
go back to reference Jones DA, Beirne AM, Kelham M, Wynne L, Andiapen M, Rathod KS, Parakaw T, Adams J, Learoyd A, Khan K, Godec T, Wright P, Antoniou S, Wragg A, Yaqoob M, Mathur A, Ahluwalia A (2024) Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial. Eur Heart J 45(18):1647–1658. https://doi.org/10.1093/eurheartj/ehae100. (PMID:38513060;PMCID:PMC11089333.5)CrossRefPubMedPubMedCentral Jones DA, Beirne AM, Kelham M, Wynne L, Andiapen M, Rathod KS, Parakaw T, Adams J, Learoyd A, Khan K, Godec T, Wright P, Antoniou S, Wragg A, Yaqoob M, Mathur A, Ahluwalia A (2024) Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial. Eur Heart J 45(18):1647–1658. https://​doi.​org/​10.​1093/​eurheartj/​ehae100. (PMID:38513060;PMCID:PMC11089333.5)CrossRefPubMedPubMedCentral
6.
go back to reference Peguero JG, Cornielle V, Gomez SI, Issa OM, Heimowitz TB, Santana O, Goldszer RC, Lamas GA (2014) The use of nitrates in the prevention of contrast-induced nephropathy in patients hospitalized after undergoing percutaneous coronary intervention. J Cardiovasc Pharmacol Ther 19(3):310–314. https://doi.org/10.1177/1074248413515077. (Epub 2013 Dec 23 PMID: 24367008)CrossRefPubMed Peguero JG, Cornielle V, Gomez SI, Issa OM, Heimowitz TB, Santana O, Goldszer RC, Lamas GA (2014) The use of nitrates in the prevention of contrast-induced nephropathy in patients hospitalized after undergoing percutaneous coronary intervention. J Cardiovasc Pharmacol Ther 19(3):310–314. https://​doi.​org/​10.​1177/​1074248413515077​. (Epub 2013 Dec 23 PMID: 24367008)CrossRefPubMed
7.
go back to reference Abdollahi Moghaddam A, BaradaranRahimi V, Morovatdar N, Rezaee R, Babalhekam SA (2023) Oral nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial. Int Urol Nephrol 55(9):2327–2334. https://doi.org/10.1007/s11255-023-03541-0. (Epub 2023 Mar 7 PMID: 36881267)CrossRefPubMed Abdollahi Moghaddam A, BaradaranRahimi V, Morovatdar N, Rezaee R, Babalhekam SA (2023) Oral nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial. Int Urol Nephrol 55(9):2327–2334. https://​doi.​org/​10.​1007/​s11255-023-03541-0. (Epub 2023 Mar 7 PMID: 36881267)CrossRefPubMed
Metadata
Title
Are inorganic nitrates the key to preventing contrast-induced nephropathy?
Authors
Asad Gul Rao
Mahek Kataria
Ghazal Ishaque
Publication date
17-06-2024
Publisher
Springer Netherlands
Published in
International Urology and Nephrology
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-024-04123-4
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare